Since menin inhibition has a similar effect on total cellular cholesterol levels compared to LXR agonists, yet likely acts via a different mechanism than direct LXR agonists, it is possible that MIs could have anti-cancer effects with fewer adverse effects. This evidence concerns the gene MEN1 and cancer.